NCT06103695已完成4 期
Open Label, Observational Study, Evaluating VTAMA® (Tapinarof) Cream, 1% QD in Psoriasis Patients Being Treated With Biologic Agents.
Psoriasis Treatment Center of Central New Jersey1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2023年2月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Body surface area ≤1%
研究概览
简要总结
Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adult ≥ 18 years of age;
- •Diagnosis of chronic plaque-type
- •Patient with ≥3% BSA
- •Patient has been treated with biologic for a minimum of 24 weeks
- •Able and willing to give written informed consent prior to performance of any study-related procedures.
排除标准
- •Patient not receiving biologic agent, or receiving biologic agent <24weeks
研究组 & 干预措施
Vtama
Other
open label Vtama
干预措施: Tapinarof (Drug)
结局指标
主要结局
Body surface area ≤1%
时间窗: 12 weeks
Patients who achieve body surface area of ≤1%
次要结局
未报告次要终点
研究者
Jerry Bagel
MD, MS
Psoriasis Treatment Center of Central New Jersey
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck RegionPsoriasisNCT05789576Organon and Co31
已完成
4 期
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque PsoriasisPsoriasisNCT05680740Organon and Co34
进行中（未招募）
3 期
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsPlaque PsoriasisNCT05172726Organon and Co58
已完成
2 期
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT00619268Centre Leon Berard160
进行中（未招募）
3 期
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerSmall Cell Lung Cancer (SCLC)NCT05740566Amgen509